MOESM5 of Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study
Additional file 5. Hazard ratio according to type of oral anticoagulation among atrial fibrillation patients with CKD when not censoring at shift or discontinuation of oral anticoagulation.
Laugesen, E. K., Staerk, L., Carlson, N., Kamper, A-L., Olesen, J. B., Torp-Pedersen, C., Gislason, G. & Bonde, A. N., 12 Nov 2019, In: Thrombosis Journal.17, 1, 8 p., 21.
Research output: Contribution to journal › Journal article › Research › peer-review
Torp-Pedersen, C. (Creator), Olesen, J. B. (Creator), Bonde, A. N. (Creator), Staerk, L. (Creator), Carlson, N. (Creator), Laugesen, E. K. (Creator), Kamper, A. (Contributor), Gislason, G. (Creator) (2019). MOESM5 of Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study. Figshare. 10.6084/m9.figshare.10288126.v1